---
title: "Chugai posts transcript of FY2026 Q2 financial results conference call"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293904228.md"
description: "Chugai Pharmaceutical reported FY2026 Q2 results, with H1 revenue rising 14.7% to JPY 663.3 billion and core operating profit up 21% to JPY 329.1 billion. The company maintained its full-year forecast, citing strong export growth driven by Hemlibra and NEMLUVIO momentum. Royalties from Foundayo began in Q2 following the US obesity launch. Pipeline updates included Phase III starts for NXT007 and first patient dosing for AQUA07."
datetime: "2026-07-27T08:54:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293904228.md)
  - [en](https://longbridge.com/en/news/293904228.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293904228.md)
generator: "portal-rs"
---

# Chugai posts transcript of FY2026 Q2 financial results conference call

-   Chugai Pharmaceutical hosted its FY2026 Q2 results webcast July 24 with CEO Osamu Okuda, CFO Iwaaki Taniguchi, and other executives. \* H1 revenue rose 14.7% to JPY 663.3 billion; core operating profit increased 21% to JPY 329.1 billion; full-year forecast maintained. \* Management cited export growth led by Hemlibra; other revenue rose JPY 29.8 billion on one-time income, Hemlibra royalties, NEMLUVIO royalties. \* NEMLUVIO momentum highlighted; Galderma reported H1 global sales of USD 433 million; Foundayo royalties began in Q2 following US obesity launch. \* Pipeline updates included two Phase III starts for NXT007; AQUA07 first patient dosed; PiaSky aHUS filings targeted in Japan, US, Europe. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md)
- [4519.JP](https://longbridge.com/en/quote/4519.JP.md)

## Related News & Research

- [Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edema](https://longbridge.com/en/news/296868472.md)
- [Chugai licenses anti-dengue antibody AID351 to GSK in exclusive deal](https://longbridge.com/en/news/296167792.md)
- [JAGX: Q2 2026 revenue fell 60% year-over-year as focus shifted to rare disease drug development](https://longbridge.com/en/news/296396312.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [Duell launches 2026-2028 performance share plan worth up to 130,000 shares](https://longbridge.com/en/news/296904059.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**